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Abstract 
  
A facile one pot, four component domino reaction between 2-(2-
bromoethyl)benzaldehyde, isocyanide, amine and sodium azide has been developed for the 
synthesis of novel tetrazolyl tetrahydroisoquinoline derivatives.  The domino sequence involves 
intramolecular replacement of halide by iminium nitrogen followed by azide-ugi reaction.  The 
developed reactions proceeded cleanly in a rapid manner to afford the corresponding tetrazolyl 
tetrahydroisoquinoline scaffolds with high to excellent yields.  
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A Facile One-Pot Protocol for the Synthesis of Tetrazolyl 
Tetrahydroisoquinolines via novel Domino Intramolecular 
Cyclization/Azide-Ugi Sequence 
Introduction 
     The build/couple/pair strategy is particularly attractive for achieving scaffold diversification 
when ring-closing reactions are coupled with known MCRs.1  Efficient construction of molecular 
complexity via domino or cascade, multicomponent reactions has recently drawn significant 
attention in the synthetic community due to its “green” nature.  Moreover, improving already 
known MCRs also is of substantial interest in the domain of organic synthesis.2  The use of 
relatively simple starting materials to drastically increase the levels of molecular complexity may 
be achieved in a single-pot operation by allowing reactive products to continue additional 
chemical transformations before workup.1   MCRs allow the creation of several bonds in a single 
operation and offer remarkable advantages like convergence, operational simplicity, facile 
automation, reduction in the number of steps, work up, extraction and purification and hence 
minimize waste generation, rendering the transformation green.  MCRs also allow considerable 
savings towards solvent, and waste disposal, as well as time consumed during work-ups and 
purifications.1  MCRs play crucial role in diversity-oriented synthesis (DOS) and biology-
oriented synthesis (BIOS) for effective synthesis of bio-relevant functional molecular libraries. 
     Today the majority of MCR chemistry performed with isocyanides, relates to the classical 
reactions of Passerini and Ugi.  Indeed, the large number of different scaffolds now available 
mostly builds on these two MCRs and their combination with other types of reactions3.  
Isocyanides are considered as highly “unpleasant” compounds, due to their intensive odour.   
Unfortunately, this is true for most commercially available isocyanides.  However, higher 
molecular weight isocyanides are often solid and odorless.  Moreover, yielding to the common 
prejudice, only a few isocyanides are commercially available.  Isocyanides can be easily 
prepared in one or two steps from their primary amine precursors.3  They are highly reactive 
biphilic one carbon synthons. Till date Ugi MCR is the most versatile multicomponent reaction 
ever known.  While most chemical reactions have their own scope and limitation, whereas the 
Ugi-4CR can convert almost all combinations of adducts into their products.5  After the 
discovery of Ugi reaction various modifications of the same have been developed.6  However, 
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the use of components other than carboxylic acids has been very less.  One of the reasons why 
carboxylic acid is plays an important role in this reaction, mechanistically it involves itself in the 
activation of the imine followed by addition of an isocyanide and trapping of the resulting 
nitrilium intermediate by the carboxylate to afford the final product by migration of the acyl 
group onto the nitrogen atom originating from the imine. Therefore, a carboxylic acid is 
necessary for the reaction of an isocyanide with an imine in the Ugi reaction, i.e., the use of a 
carboxylic acid limits application of this reaction to the construction of a broad range of 
molecules.7,8 
      However, after considering these issues, an azide compound was chosen for the isocyanide 
based multicomponent reaction.  Ugi first reported, the reaction of aldehyde with an isocyanide 
in the presence of hydrazoic acid instead of a carboxylic acid afforded 1H-tetrazoles via 1, 3-
dipolar cycloaddition between a nitrilium intermediate and hydrazoic acid.7,8  Several methods 
have been developed for the synthesis of 1, 5-disubstituted tetrazoles.9  But till date the use of 
Ugi reaction can be claimed to be the best way to generate 1,5-disubstituted tetrazole moieties.  
        
   
           
        
             
 
fused tetrazolo-ketopiperazines10 
fused azepino-tetrazoles11 
fused 4,5-dihydrotetrazolo[1,5-a]quinoxalines12 
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Figure 1: Ugi reactions which have yielded diverse tetrazole based scaffolds13 
     In the context of our MCR chemistry we aimed to construct structurally complex scaffolds by 
merging compatible reactions in a cascade manner, which may provide great opportunities for 
the development of novel synthetic routes to natural products and drug candidates with 
remarkable synthetic efficiency.  To the best of our knowledge there are no reports for the 
synthesis of novel tetrahydroisoquinoline containing tetrazole moiety in one-pot fashion from 
easily available starting materials. 
Biological and pharmaceutical importance 
 
 Figure 2: Tetrazole substituted with tetrahydroisoquinoline unit 
The chemistry of heterocycles lies at the heart of drug discovery.  Many known biological 
active compound contain heterocyclic core, which are indispensable element for bio-activity.14   
Among all aromatic heterocycles the chemistry of functionalized N-heterocycles in particular 
tetrazoles continues to be of interest because of the industrial and biological importance of these 
class of compounds.  They can also act as a pharmacophore for the carboxylate group, increasing 
their utility.  Tetrazole and its derivatives are used for biological activities such as antifungal, 
antibacterial, anti-inflammatory antiviral, antitubercolous, cyclooxygenase inhibitor; 
antinociceptive, hypoglycemic and anticancer activities.15  Tetrazole analogues are reported to 
exhibit biological activity toward the cannabinoid-1 receptor (CB1), fatty acid amide hydrolase, 
melanin-concentrating hormone receptor 1, polo-like kinase 1, and to act as orally effective 
human growth hormone secretagogues.  Cis-amide bonds have been shown to play key roles in 
protein secondary structures involved in several important biological systems.15  In studies to 
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determine effective mimics of the cis-amide bond, the tetrazole ring and more specifically the 
1,5-disubstituted tetrazole, has proven to be a valuable.13 
 
Figure 3: Some pharmaceutically important Tetrazoles16 
 
     Substituted 1,2,3,4-tetrahydroisoquinolines are substances of both natural and synthetic origin 
Isoquinoline alkaloids, especially 1,2,3,4-tetrahydroisoquinolines (THIQs), have long attracted 
significant attention due to their biological activity and also because they are important building 
blocks in natural product synthesis and drug discovery.  In humans these  chiral N-heterocyclic 
scaffolds affect many physiological and pathological processes, hence they have high medicinal 
value..17  
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Figure 4: Some pharmaceutically important THIQs 
      Survey of literature reveals that when one biodynamic heterocyclic system was coupled with 
another a molecule with enhanced biological activity was produced.   The chemistry of these 
linked biheterocycles has been the fascinating field of investigation in medicinal chemistry, as 
they have been found to exhibit enhanced biological profile.21   Keeping in view of high potential 
of 1,2,3,4-tetrahydroisoquinolines and tetrazoles as drug candidates the synthesis of some novel 
derivatives of tetrazole substituted 1,2,3,4-tetrahydroisoquinolines was undertaken which are 
expected to be studied later for their medicinal properties. 
Results and Discussion 
     Initially, we have performed the reaction between 2-(2-bromoethyl)benzaldehyde 1, aniline 
2a, t-butylisocyanide 3a and azidotrimethylsilane 4 in methanol at room temperature, 
surprisingly, the first attempt provided the expected product (5a) in 20% yield (Table 1, entry 1).  
In order to optimize reaction conditions, we varied the equivalents of the azide component and 
the isocyanide components and saw only marginal increase in yields (entries 2 and 3).  Higher 
concentration of reaction mixture also failed to improve the yield (entry 4).   The attempt of 
solvent-free condition and heating with microwave/ultrasound was not useful.  Surprisingly, by 
replacing azidotrimethylsilane with cheaper sodium azide drastically improved the yield and 
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gave the desired product in 86% yield within 10 min (entry 10).  By increasing further 
concentration of reaction mixture, we achieved the higher yield of the product (96%) (entry 11), 
which also reduced the reaction time to 5 min.  The study for optimizing conditions is depicted in 
Table 1. 
Table 1: Optimization of reaction conditiona 
 
Entry      1a 
(Equiv.) 
    2a 
(Equiv.) 
    3a 
 (Equiv.) 
     N-3 
(Equiv.) 
Condition Time 
(Min) 
Yield(%)b 
(5a) 
1 1 1 1 1  (TMSN3) MeOH (5mL), rt 5 20 
2 1 1 1.1 1.1 (TMSN3) MeOH (5mL), rt 15 25 
3 1 1 1.5 1.5 (TMSN3) MeOH (5mL), rt 15 44 
4 1 1 1.5 1.5(TMSN3) MeOH (2mL), rt 15 50 
5 1 1 1.5 1.5 (TMSN3) Neat reaction, rt 15 24 
6 1 1 1.5 1.5 (TMSN3) Microwave,            
50 °C (No Solvent) 
10 - 
7 1 1 1.5 1.5 (TMSN3) Sonication, rt  
(solvent-free) 
25 32 
8 1 1 1.5 1.5 (TMSN3) MeOH (5mL), 40 °C  25 33 
9 1 1 1.5 1.5 (TMSN3) MeOH (5mL), reflux 30 - 
10 1 1 1 1 (NaN3) MeOH (5mL) 10 86 
11 1 1 1 1 (NaN3) MeOH (2mL), rt 5 96 
12 1 1 1 1(NaN3) Neat reaction, rt 20 - 
 
a
 All reactions were performed with 0.23 mmol of the aldehyde 1 as limiting reagent. b Isolated yield of 
chromatographically pure product. 
 
  
     With the optimal condition established, we explored the generality of the reaction by applying 
the methodology to the strong donating as well as withdrawing aromatic amines 3, which gave 
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the corresponding products in high to excellent yield.  In case of strong withdrawing nitro-amine, 
the reaction failed to give the desired product, which can be reasoned that, lack of lone pair 
availability for intramolecular amination reaction.  The reaction proceeded in a facile manner 
with both t-butylisocyanide and cyclohexylisocyanide.  The product formation was confirmed by 
FT-IR, NMR spectral analysis. 
 
Table 2   The scope of the amines and isocyanidesa,b 
 
 
a
 All reactions were performed with 0.23 mmol of the aldehyde as limiting reagent. b Isolated yield of 
chromatographically pure product. 
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     After successful accomplishment of this method we turned to the illustration of the reaction 
mechanism (Figure 5).  Initially the aldehyde 1 and amine 2 react to give an imine A followed by 
intramolecular nucleophilic substitution with elimination of Br- to form Mannich base B (isolated 
and characterised).  The electrophilic Mannich base B is then attacked by the isocyanide 3 to 
form intermediate C, which on neutralisation by the azide anion and further cycloaddition7 can 
give product 5.   
     In order to prove the proposed mechanism, we have did controlled experiment without adding 
isocyanide and sodium azide, which gave intermediate B, which on further treatment with 
isocyanide 3 and sodium azide 4 gave product in excellent yield, supports the proposed plausible  
mechanism.  
 
Figure 5: Plausible reaction mechanism. 
Conclusion 
       In summary a very simple and efficient four component reaction for the synthesis of 
tetrazolo substituted tetrahydroisoquinoline has been achieved via intramolecular 
cyclization/azide-Ugi sequence.  Present methodology shows wide substrate scope with high to 
excellent yield.  The salient features of this method is excellent yields, short reaction time, 
cleaner reaction profile, high bond forming index (BFI), and the use of inexpensive and readily 
available starting material.  We believe that, this method could be very useful for biology-
oriented combinatorial synthesis (BIOS).   
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Experimental section 
General information 
      In this section the preparations of all the compounds that have been made in the course of 
thesynthesis of tetrazolyl tetrahydroisoquinolines have been discussed.  For the experiments, all 
starting material and reagents are purchased from standard commercial sources or were prepared 
in  the laboratory.  All the glasswares were cleaned with soap water followed by acetone and 
dried in hot air oven at 100 ˚C for 2h.  Solvents were distilled prior to use; petroleum ether with a 
boiling point range 40-60 ˚C was used. 
     IR spectra were recorded on the Bruker Tensor 37 (FTIR) spectrophotometer.  1H NMR 
spectra were recorded on Bruker Avance 400 (400 MHz) spectrometer at 295K in CDCl3;  
chemical shifts value (δ ppm) and coupling constants (Hz) are reported in standard fashion with 
reference to either tetramethylsilane (TMS) (δ-H = 0.00 ppm) or CHCl3 (δ-H = 7.26ppm).  13C 
NMR spectra were recorded on Bruker Avance 400 (100 MHz) spectrometer at 298K in CDCl3; 
chemical shifts (δ ppm) are reported relative to CHCl3 [(δ-C=77.00ppm) central line of triplet].  
In 13C NMR the nature of carbons (C, CH, CH2, and CH3) was determined by recording the 
DEPT- 135 spectra.   In 1H NMR, the following abbreviations were used throughout the thesis; s 
= singlet, d = doublet, t = triplet, q = quartet, qui = quintet, m = multiplet and br.s = broad 
singlet. The assignment of the signals was confirmed by 1H, 13C and DEPT spectra.  Reactions 
were monitored by TLC on silica gel (254 mesh) using a combination of petroleum ether and 
ethyl acetate as eluents. 
 
Preparation of starting material 
1)  General Procedure for preparation of isochromans.22 
 
     A mixture of the substituted phenylethyl alcohol (4.97 mmol), chloromethyl methyl ether 
(7.046 mmol) and N,N-diisopropylethylamine (9.95 mmol)  in dry dichloromethane (15 ml)  was 
stirred under nitrogen atmosphere for 2.5 h at rt. The reaction mixture was then washed with 
water, dried (Na2SO4) and the solvent was removed in vaccuo.  The crude MOM acetal was 
dissolved in dried acetonitrile and added to cooled (0 oC) solution of trimethylsilyl 
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trifluoromethanesulfonate (TMSOTf).  The reaction was carried out under nitrogen atmosphere 
for 3h. Then the mixture was quenched by the addition of l M NaHCO3.  The organic phase was 
washed with brine, dried with sodium sulphate and evaporated under reduced pressure.  
Purification by column chromatography afforded corresponding substituted isochromans. 
2) General procedure for the preparation of benzaldehydes: 22 
 
     To a solution of the substituted isochroman (7.46 mmol) derivatives in acetonitrile (15 ml), 
CuBr2 (8.95 mmol) was added under nitrogen atmosphere. The solution was refluxed for about 
2hr and then cooled to room temperature.  The reaction mixture was added water, extracted with 
ethyl acetate.  The combined organic extracts were washed with brine and dried with Na2SO4, 
filtered and concentrated and then purified by silica gel column chromatography to afford the 
product. 
 
Representative experimental procedure for the synthesis of 1-(1-tert-butyl-1H-tetrazol-5-
yl)-1,2,3,4-tetrahydro-2-phenylisoquinoline 5a : 2-(2-bromoethyl)benzaldehyde 1a (50 mg, 
0.232 mmol) and 2a aniline (21.6 mg, 0.232 mmol) were taken in an 5 mL round bottom flask 
and then stirred for 2 min to form the solid mannich base, then 2 mL of methanol was added to 
dissolve the solid.  Then sodium azide (15.11 mg, 0.232 mmol) and t-butyl isocyanide 3a (19 
mg, 0.232 mmol) were added in succession to the reaction mixture and monitored the completion 
reaction by TLC.  After completion of the reaction, the methanol solvent was completely 
evaporated under reduced pressure.  Then the reaction mixture was extracted with ethyl acetate 
(2 X 20 ml). The extracted layer was washed with brine solution and allowed to dry over 
Na2SO4.  The crude extract was purified by filtration through a silica gel (100-200 mesh) column 
using hexane and ethyl acetate as eluents to yield the desired product 5a as a white solid (74.3 
mg, 96% yield).  
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Spectral data  
 
  
 1-(1-Tert-butyl-1H-tetrazol-5-yl)-1,2,3,4-tetrahydro-2-phenylisoquinoline (5a) : white solid; 
mp 260-262 °C; 74.3 mg; 96% yield;  IR (MIR-ATR, 4000-600 cm-1): νmax = 3062, 2978, 2925, 
2154, 1494, 758, 740, 695 cm-1; 1H NMR (400 MHz, CDCl3)  ppm = 1.71 (s, 9H), 2.61 - 2.70 
(m, 1H), 2.83 (ddd,  J = 17.1, 11.0 and 6.6 Hz, 1H), 3.52 - 3.72 (m, 2H), 6.15 (s, 1H), 6.92 - 7.01 
(m, 3 H), 7.01 - 7.08 (m, 1H), 7.15 (d, J = 6.8 Hz, 1H), 7.18 - 7.26 (m, 3H);  13C NMR (100 
MHz, CDCl3)  ppm = 24.5, 29.8, 45.4,53.8, 62.2, 76.7, 77.0, 77.4, 119.8, 121.8, 126.4, 127.7, 
127.8, 128.1, 129.1, 129.5, 129.7, 132.3, 135.3, 149.0, 155.4. 
 
 
1-(1-Cyclohexyl-1H-tetrazol-5-yl)-1,2,3,4-tetrahydro-2-phenylisoquinoline (5b) : white solid; 
mp 174-176 ºC; 70.8 mg; 85% yield; IR (MIR-ATR, 4000-600 cm-1): νmax  = 3061, 3026, 2934, 
2858, 1597, 1495, 750, 733, 698 cm-1;  1H NMR (CDCl3, 400 MHz): δ ppm = 0.85 - 1.04 (m, 
3H), 1.12 - 1.35 (m, 3H), 1.53 - 1.77 (m, 5H), 1.82 - 1.93 (m, 2H), 3.02 (dt, J = 16.5 and 4.9 Hz, 
1H), 3.20 (ddd, J = 16.1, 7.8 and 4.9 Hz, 1H), 3.45 (ddd, J = 12.6, 7.9 and 4.4 Hz, 1H), 3.68 - 
3.77 (m, 1H), 4.41 (tt,  J = 11.74 and 3.9 Hz, 1H), 6.22 (s, 1H), 6.88 - 6.98 (m, 2H), 7.05 - 7.10 
(m, 2H), 7.11 - 7.18 (m, 1H), 7.21 - 7.28 (m, 3H);  13C NMR (100 MHz, CDCl3) δ  ppm = 14.4, 
22.2, 25.0, 25.0, 25.9, 29.2, 31.9, 32.6, 32.9, 49.4, 55.2, 58.5, 77.3, 77.6, 120.7, 123.0, 126.9, 
127.9, 128.0, 129.5, 129.6, 132.5, 134.9, 149.61, 154.8. 
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2-(2-Bromophenyl)-1-(5-cyclohexyl-5H-1,2,3-triazol-4-yl)-1,2,3,4-tetrahydroisoquinoline 
(5c) : white solid; mp 224-226 ºC; 97.4 mg; 96% yield; IR (MIR-ATR, 4000-600cm-1): νmax = 
3060,2934, 2857,1452, 1027, 812, 793, 733, 702, 671 cm-1;  1H NMR (400 MHz, CDCl3)  ppm 
= 0.51 - 0.60 (m, 1H), 0.79 - 0.96 (m, 1H), 1.05 - 1.18 (m, 1H), 1.20 - 1.47 (m, 2H), 1.49 - 1.64 
(m, 2H), 1.67 - 1.77 (m, 1H), 1.78 - 1.92 (m, 2H), 2.97 (dt, J = 16.1 and 3.2 Hz, 1H), 3.08 (ddd, J 
= 12.2, 10.3 and 3.4 Hz, 1H), 3.55 (ddd, J = 15.8, 10.4 and 5.1 Hz, 1H), 3.75 - 3.88 (m, 1H), 4.53 
(tt, J = 11.7 and 3.7 Hz, 1H), 6.43 (s, 1H) 6.74 (d, J = 8.3 Hz, 1H), 6.91 (td, J = 7.7 and 1.7 Hz, 
1H), 7.06 - 7.14 (m, 2H), 7.19 - 7.26 (m, 1H), 7.29 (s, 1H) 7.36 (d, J = 7.8 Hz, 1H), 7.54 (dd, J = 
7.8 and 1.5 Hz, 1H);  13C NMR (100 MHz, CDCl3)  ppm = 24.8, 25.4, 25.5, 29.6 ,32.1, 32.4, 
51.0, 54.9, 57.9, 76.8, 77.1, 77.4, 120.7,123.2, 125.9, 126.54, 127.7, 128.4, 129.3, 132.5,133.9, 
134.6, 146.8, 153.8.  
 
 
1-(1-Tert-butyl-1H-tetrazol-5-yl)-2-(2-bromophenyl)-1,2,3,4-tetrahydroisoquinoline (5d) : 
pale yellow solid; mp 200-202 °C; 85.1 mg; 90% yield; IR (MIR-ATR, 4000-600cm-1): νmax = 
3062, 2982, 2939, 2831, 1474, 758, 738, 673 cm-1; 1H NMR (400 MHz, CDCl3)  ppm  = 1.64 
(br s., 9H), 2.81 - 2.91 (m, 2H), 3.50 (br. s, 1H), 3.91 (br s, 1H), 6.03 (br. s, 1H), 6.96 (t, J = 7.6 
Hz, 3H), 7.10 - 7.19 (m, 3H), 7.21 - 7.26 (m, 1H); 13C NMR (100 MHz, CDCl3)  ppm = 29.7, 
55.1, 62.3, 76.7, 77.3, 116.3, 116.5, 122.4, 124.4, 124.4, 124.6, 126.5, 127.3, 127.8, 129.7, 132.6, 
135.1, 137.1, 137.2, 155.0. 
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1-(1-Cyclohexyl-1H-tetrazol-5-yl)-2-(2-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline (5e) : 
Pale yellow solid; mp 230–232 ºC; 79.9 mg; 89% yield; IR (MIR-ATR, 4000-600 cm-1): νmax = 
3065, 2935, 2858, 1500, 749, 731 cm-1; 1H NMR (400 MHz, CDCl3)  ppm = 0.69 (d,  J = 12.7 
Hz, 1H), 0.76 - 0.94 (m, 1H),  1.07 (qt,  J = 12.8 and 3.0 Hz, 1H), 1.16 - 1.32 (m, 3H), 1.32 - 
1.45 (m, 2H), 1.50 - 1.61 (m, 1H), 1.67 - 1.82 (m, 2H),  2.90 (dt, J = 16.0 and 3.5 Hz, 1H), 3.14 - 
3.33 (m, 1H), 3.61 (dt,  J = 11.6 and 4.5 Hz, 1H), 4.45 (tt,  J = 11.7 and 3.7 Hz, 1H), 6.24 (s, 
1H), 6.76 (d,  J = 8.3 Hz, 1H), 6.87 - 6.93 (m, 3H), 6.93 - 6.98 (m, 1H), 7.02 - 7.07 (m, 1H), 7.08 
- 7.15 (m, 1H), 7.15 - 7.21 (m, 1H); 13C NMR (100 MHz, CDCl3)  ppm = 24.8, 25.4, 29.3, 32.1, 
32.5, 49.5, 54.5, 58.1, 76.7, 77.3, 116.0, 116.2, 122.6, 124.5, 124.9, 125.0, 126.6, 127.4, 127.6, 
129.2, 132.2, 134.3, 136.7, 136.8, 153.9, 155.6, 158.1. 
 
 
 1-(1-Tert-butyl-1H-tetrazol-5-yl)-2-(2-fluorophenyl)-1,2,3,4-tetrahydroisoquinoline (5f) : 
Pale yellow solid; mp 222-224 °C; 69.3 mg; 85% yield; IR (MIR-ATR, 4000-600cm-1): νmax = 
3063, 2983, 2939, 1499, 1228, 753, 735 cm-1; 1H NMR (400 MHz, CDCl3)  ppm =  1.66 (s, 
9H), 2.69 - 2.90 (m, 2H), 3.34 - 3.54 (m, 1H), 3.54 - 3.76 (m, 1H), 6.05 (br. s, 1H), 6.85 - 7.10 
(m, 4H), 7.17 - 7.40 (m,  3H); 13C NMR (100 MHz, CDCl3)  ppm = 29.7, 55.1, 62.3, 76.7, 77.3, 
116.3, 116.5, 122.4, 124.4, 124.4, 124.6, 126.5, 127.3, 127.8, 129.7, 132.6, 135.1, 137.1, 137.2, 
155.0. 
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1-(1-Cyclohexyl-1H-tetrazol-5-yl)-1,2,3,4-tetrahydro-2-(3,4,5 
trimethoxyphenyl)isoquinoline (5g) :  Yellow solid; mp 150-152 ºC, 79.2 mg; 76% yield, IR 
(MIR-ATR, 4000-600 cm-1): νmax = 2934, 2857, 1586, 1507, 1451, 1236, 1124 cm-1;  1H NMR 
(400 MHz, CDCl3)  ppm = 0.81 - 1.06 (m, 2H), 1.12 - 1.39 (m, 2H), 1.51 - 1.77 (m, 3H), 1.79 - 
1.96 (m, 3H), 1.99 - 2.20 (m, 2H), 3.00 - 3.15 (m, 1H), 3.24 - 3.43 (m, 2H), 3.75 - 3.96 (m, 9H),  
4.44 (tt, J = 11.7 and 3.7 Hz, 1H), 6.16 (s, 1H),  6.28 (s, 2H), 6.83 (d, J = 7.8 Hz, 1H), 7.01 - 
7.18 (m, 2H), 7.22 - 7.44 (m, 1H); 13C NMR (100 MHz, CDCl3)  ppm  = 14.1, 20.2, 24.7, 25.3, 
25.3, 29.5, 32.0, 32.3, 51.1, 54.9 , 57.7, 60.3, 76.7, 77.3, 120.3, 122.6, 126.3, 127.2, 127.5, 128.8, 
129.2, 132.5, 134.1, 134.5, 135.9, 144.0, 153.7. 
 
 
1-(1-Tert-butyl-1H-tetrazol-5-yl)-1,2,3,4-tetrahydro-2-(3,4,5-trimethoxyphenyl)isoquinoline 
(5h) :  White solid; mp 218-220 ºC; 78.5 mg; 80% yield, IR (MIR-ATR, 4000-600cm-1): νmax = 
3059, 2980, 2931, 1493, 758, 695 cm-1; 1H NMR (CDCl3, 400 MHz): δ ppm = 1.26 (d, J = 2.45 
Hz, 9H), 2.26 (s,  9H), 3.32 (t, J = 5.38 Hz, 1H), 4.74 (br. s, 1H), 5.43 (s, 1H), 7.35 - 7.42 (m, 
1H), 7.75 - 7.91 (m, 1H), 8.19 (d, J = 9.29 Hz, 1H), 8.61 (d, J = 2.45 Hz, 2H), 9.31 (d, J = 7.34 
Hz, 1H); 13C NMR (CDCl3, 100MHz): ppm = 24.8, 31.0, 40.3, 47.2, 49.8, 56.4, 61.8, 124.3, 
128.3, 130.5, 133.3, 134.1, 136.8, 138.7, 140.3, 149.3, 152.2, 158.1, 168.8, 171.3, 175.8, 180.2. 
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2-(2-Bromo-4-methylphenyl)-1-(1-cyclohexyl-1H-tetrazol-5-yl)-1,2,3,4-tetrahydro-
isoquinoline  (5i) : White solid;  mp 180-182 °C, 103.9 mg; 99% yield, IR (MIR-ATR, 4000-
600 cm-1): νmax = 3028, 2933, 2857, 1491, 1451, 745, 730 cm-1; 1H NMR (400 MHz, CDCl3)  
ppm = 0.56 (d, J = 12.2 Hz,  1H), 0.81 - 0.93 (m, 1H), 1.06 - 1.18 (m, 1H), 1.23 - 1.44 (m, 2H), 
1.49 - 1.62 (m, 2H), 1.70 - 1.77 (m, 3H), 1.78 - 1.91 (m, 2H),  2.04 (m, 3H), 2.21 (s, 3 H), 2.91 - 
3.08 (m, 2H), 3.54 (ddd, J  = 15.77, 10.39 and 4.65 Hz, 1H), 3.72 - 3.78 (m, 1H), 4.50 - 4.60 (m, 
1H), 6.39 (s, 1H),  6.72 (d, J = 7.8 Hz, 1H), 6.99 (dd, J  = 8.5 and 1.7 Hz, 1H), 7.09 (t, J = 7.34 
Hz, 1H), 7.19 - 7.25 (m, 2H), 7.28 (s, 1H), 7.36 (d, J = 1Hz, 1H); 13C NMR (100 MHz, CDCl3)  
ppm = 14.1, 20.2, 24.7, 25.3, 25.3, 29.5, 32.0, 32.3, 51.1, 54.9, 57.7, 60.7, 76.7, 77.3, 120.3, 
122.6, 126.4, 127.2, 127.5, 128.8, 129.2, 132.5, 134.1, 134.5, 135.9, 144.1, 153.7. 
 
 
1-(1-Tert-butyl-1H-tetrazol-5-yl)-2-(2-bromo-4-methylphenyl)-1,2,3,4-tetrahydro-
isoquinoline (5j) : Pale brown solid, 96.9 mg; mp 260-262 ºC; 98% yield; IR (MIR-ATR, 4000-
600cm-1): νmax = 2980, 2924, 1491, 1239, 772, 742 cm-1; 1H NMR (400 MHz, CDCl3)  ppm = 
1.66 (br. s, 9H), 2.25 (s, 3H), 2.74 (br. s, 1H), 2.78 - 2.91 (m, 1H),  3.45 (br. s, 1H), 3.86 (br. s, 
1H), 5.98 (br. s, 1H), 6.70 (br. s, 1H), 6.92 (d, J = 7.3 Hz, 2H),  7.12 - 7.25 (m, 2H), 7.27 (br. s, 
1H),  7.40 (s, 1H); 13C NMR (100 MHz, CDCl3)  ppm = 20.2, 30.2, 43.1, 55.4, 76.7, 77.3, 
120.5, 123.8, 126.3, 126.8, 127.5, 129.0, 134.3, 135.8, 145.2, 154.9. 
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1-(1-Tert-butyl-1H-tetrazol-5-yl)-1,2,3,4-tetrahydro-2-(2,4-dimethylphenyl)isoquinoline 
(5m) : White solid;  mp 196-198 °C; 60.4 mg; 72% yield; IR (MIR-ATR, 4000-600 cm-1): νmax = 
2298, 2938, 1500, 1374, 1208, 1110, 942, 816, 743 cm-1; 1H NMR (400 MHz, CDCl3)  ppm = 
1.54 (br. s, 9H), 2.14 (s, 3H), 2.17 (s, 3H) 2.65 - 2.81(m, 1H), 3.02 (m, 1H), 2.99 (m, 1H), 3.80 
(br. s, 1H), 5.87 (br. s, 1H), 6.57 (br. s, 1H), 6.73 (d, J = 7.8 Hz, 2H) 6.93 (s, 1H), 7.05 - 7.21 (m, 
3H);  13C NMR (100 MHz, CDCl3)  ppm = 17.7, 20.7, 30.1, 47.6, 55.7, 76.7, 77.3, 126.2, 126.7, 
127.2, 127.4, 128.50, 129.7, 132.0, 133.8, 133.9, 135.8, 136.3, 138.7, 145.9. 
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Figure 6.  1H NMR (400 MHz) spectrum of compound 5a in CDCl3. 
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Figure 7.  13C NMR (400 MHz) spectrum of compound 5a in CDCl3. 
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Figure 8.  1H NMR (400 MHz) spectrum of compound 5b in CDCl3. 
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Figure 9.  13C NMR (100 MHz) spectrum of compound 5b in CDCl3 
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Figure 10.  1H NMR (400 MHz) spectrum of compound 5c in CDCl3. 
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Figure 11.  13C NMR (100MHz) spectrum of compound 5c in CDCl3. 
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Figure 12.  1H NMR (400 MHz) spectrum of compound 5d in CDCl3. 
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Figure 13.  13C NMR (100 MHz) spectrum of compound 5d in CDCl3 
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Figure 14.  1H NMR (400 MHz) spectrum of compound 5e in CDCl3. 
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Figure 15.  13C NMR (100 MHz) spectrum of compound 5e in CDCl3. 
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Figure 16.  1H NMR (400 MHz) spectrum of compound 5f in CDCl3. 
160 150 140 130 120 110 100 90 80 70 60 50 40 30 20 10
Chemical Shift (ppm)
15
4.
97
13
7.
23
13
7.
15
13
5.
09
13
2.
62
12
9.
66
12
7.
76
12
7.
29
12
6.
49
12
4.
65
12
4.
47
12
4.
39
12
2.
37
11
6.
55
11
6.
34
77
.
31
77
.
00
76
.
68
62
.
32
55
.
15
29
.
75
 
Figure 17.  13C NMR (100 MHz) spectrum of compound 5f in CDCl3. 
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Figure 18.  1H NMR (400 MHz) spectrum of compound 5g in CDCl3. 
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Figure 19.  13C NMR (100 MHz) spectrum of compound 5g in CDCl3 
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Figure 20.  1H NMR (400 MHz) spectrum of compound 5h in CDCl3 
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Figure 21.  13C NMR (100 MHz) spectrum of compound 5h in CDCl3 
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Figure 22.  1H NMR (400 MHz) spectrum of compound 5i in CDCl3 
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Figure 23.  13C NMR (100 MHz) spectrum of compound 5i in CDCl3 
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Figure 24.  1H NMR (400 MHz) spectrum of compound 5j in CDCl3 
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Figure 25.  13C NMR (100 MHz) spectrum of compound 5j in CDCl3 
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Figure 26.  1H NMR (400 MHz) spectrum of compound 5m in CDCl3 
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Figure 27.  13C NMR (100 MHz) spectrum of compound 5m in CDCl3. 
